

**IN THE CLAIMS**

Please amend claims 116 and 164, as shown below. The following listing of claims replaces all prior listings.

1-115. (Canceled).

116. (Currently amended) A method for ~~enhancing~~ the delivery of a bioactive agent from the vasculature to a selected tissue in a patient, comprising:

(i) administering said bioactive agent to said patient;

(ii) administering a vesicle composition to said patient, by intravascular infusion, wherein said vesicle composition comprises, in an aqueous carrier, vesicles comprising lipids, proteins, or polymers and a gas or gaseous precursor; and

(iii) delivering said bioactive agent from the vasculature through the vessel wall and into said selected tissue by cavitating and/or rupturing said vesicles,

wherein said cavitating and/or rupturing is accomplished by applying to the patient ultrasonic energy having a frequency between about 750 kHz and 3 MHz, to thereby enhance delivery of said bioactive agent from the vasculature through the vessel wall and into said selected tissue.

117. (Previously presented) A method according to Claim 116 wherein said bioactive agent is administered to said patient at a rate which comprises continuous infusion.

118. (Previously presented) A method according to Claim 116 wherein said bioactive agent and said vesicle composition are administered to said patient substantially simultaneously.